[Effects of aminocapronic acid and small-dose trasilol on blood loss after cardiac surgery with extracorporeal circulation].
The paper presents the results of a retrospective study of small-dose (2,000,000 ECU) trasilol (Group 1) and aminocapronic acid (Group 2) on the size of postoperative blood loss in patients after cardiac surgery under extracorporeal circulation (EC). The mean postoperative blood loss was 4.7 +/- 0.2 and 4.8 +/- 0.4 ml/kg/day in Groups 1 and 2, respectively (p > 0.05). A significantly less blood loss was noted when trasilol was used in patients with normothermal prolonged EC as compared with hypothermal prolonged EC (p < 0.05), which may be associated not only with temperature conditions, but also with the significantly less mean duration of normothermal EC (113.1 +/- 3.4 and 136.9 +/- 6.0 min, respectively (p < 0.05). In Groups 1 and 2, postoperative blood loss after hypothermal prolonged EC did not differ significantly, the duration of EC being significantly higher in Group 1 patients than that in Group 2 (p < 0.02). This is indicative of the advantage of the use of trasilol in cases of prolonged hypothermal perfusion. The use of trasilol is preferable in patients with a large scope of surgical intervention under prolonged hypothermal perfusion. By taking into account the equal efficacy of trasilol and aminocapronic acid in reducing postoperative blood loss, the use of aminocapronic acid is more profitable.
Morozov
Iu A
IuA
Charnaia
M A
MA
Gladysheva
V G
VG
D000614:Aminocaproates / Q000008:administration & dosage / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004334:Drug Administration Schedule; D005112:Extracorporeal Circulation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D007611:Aprotinin